NALIRIFOX versus gemcitabine plus nab-paclitaxel in Chinese patients with advanced pancreatic adenocarcinoma: a randomized, open-label phase II trial
在中国晚期胰腺腺癌患者中，NALIRIFOX 对比吉西他滨联合白蛋白紫杉醇：一项随机、开放标签的 II 期试验
期刊:Nature Communications
影响因子:15.7
doi:10.1038/s41467-026-68409-0
Gao, Chuntao; Zhang, Yanqiao; Qu, Xiujuan; Chen, Xingyun; Zhang, Jingdong; Wu, Heshui; Sun, Meili; Zha, Yong; Wang, Junbin; Wang, Yusheng; Li, Zhihua; Gao, Jinghua; Lin, Rongbo; Zang, Aimin; Zhang, Huiqing; Yuan, Xianglin; Du, Chengyou; Zhao, Jun; Yang, Yongsheng; Shi, Xuetao; Cheng, Wei; Wang, Bangmao; Wu, Shikai; Zhao, Tiansuo; Wang, Jian; Gao, Song; Wang, Xiuchao; Ma, Weidong; Liu, Rui; Shi, Yehui; Liu, Yanping; Xie, Yijiao; Niu, Miao; Zhao, Fuchen; Yu, Jun; Hao, Jihui
